Thyroid Eye Disease

The Federal Trade Commission has sued to stop Amgen from acquiring Horizon Therapeutics, a potential blockbuster deal that could restrict marketplace competition, according to an FTC press release.

Ocular dysmotility in thyroid eye disease was significantly associated with increased total volume and decreased total density of extraocular muscles, according to a presentation at Real World Ophthalmology.

The FDA approved expanded indication language to allow the use of teprotumumab for the treatment of thyroid eye disease for any level of activity or duration, according to a press release.

Teprotumumab is associated with a greater reduction in proptosis than placebo at 24 weeks among adults with chronic thyroid eye disease and a low clinical activity score, according to topline results.

VRDN-001 demonstrated positive results at a low dose for the treatment of active thyroid eye disease in a phase 1/2 clinical trial, according to a press release from Viridian Therapeutics.

Individualized care and patient satisfaction are among the areas of emphasis in a new consensus statement on management of thyroid eye disease.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Shoaib Ugradar, MD, discusses research on the genetics behind the different stages of thyroid eye disease.